Cite
HARVARD Citation
Nishio, M. et al. (2019). KEYNOTE‐025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1–positive advanced non–small‐cell lung cancer. Cancer science. 110 (3), pp. 1012-1020. [Online].